Jefferies Maintains Doximity(DOCS.US) With Buy Rating, Raises Target Price to $88
Doximity Analyst Ratings
Leerink Partners Maintains Doximity(DOCS.US) With Buy Rating, Maintains Target Price $90
Doximity Is Maintained at Neutral by Goldman Sachs
Goldman Sachs Maintains Neutral on Doximity, Raises Price Target to $80
A Quick Look at Today's Ratings for Doximity(DOCS.US), With a Forecast Between $65 to $83
Leerink Partners Upgrades Doximity to Outperform, Raises Price Target to $90
Doximity Price Target Raised to $71.00/Share From $60.00 by Canaccord Genuity
Doximity Is Maintained at Hold by Canaccord Genuity
Doximity Is Maintained at Equal-Weight by Wells Fargo
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Doximity (DOCS)
A Quick Look at Today's Ratings for Doximity(DOCS.US), With a Forecast Between $71 to $90
Morgan Stanley Boosts Price Target on Doximity to $71 From $53, Keeps Equalweight Rating
Doximity Analyst Ratings
Needham Maintains Buy on Doximity, Raises Price Target to $82
Wells Fargo Reaffirms Their Hold Rating on Doximity (DOCS)
Analysts Are Neutral on Top Healthcare Stocks: IQVIA Holdings (IQV), Doximity (DOCS)
Doximity's Neutral Rating: Balancing Strong Q3 Performance With Cautious Future Outlook
Truist Financial Maintains Doximity(DOCS.US) With Hold Rating
BofA Securities Maintains Doximity(DOCS.US) With Hold Rating, Raises Target Price to $63